

Article 34

THE CLAIMS DEFINING THE INVENTION ARE:

- SUB B1*
1. A composition for administration to animals including a combination of :
 - (a) at least one anti-arthritis agent selected from the group comprising
 - i) green-lipped mussel extract (GLME) and/or a pharmacologically active green lipped mussel product, and
 - ii) shark cartilage; with
 - (b) at least one enhancing agent selected from the group of:
a bark product or extract exhibiting antioxidant properties, and
chondroitin compounds, and
deer velvet, and
vitamin Eand wherein the agent enhances the effect of the anti-arthritis agent.
 2. A composition for administration to animals including a combination of :
 - (a) at least one anti-arthritis agent selected from the group comprising
 - i) green-lipped mussel extract (GLME) and/or a pharmacologically active green lipped mussel product, and
 - ii) shark cartilage; with
 - (b) at least one enhancing agent selected from the group of:
a bark product or plant product or extract exhibiting antioxidant properties,
and
chondroitin compounds, and
deer velvet, and
vitamin Eand wherein the agent enhances the effect of the anti-arthritis agent.
 3. A composition as claimed in either claim 1 or claim 2 which includes either or both of a green-lipped mussel extract (GLME) and a pharmaceutically active green lipped mussel product, in combination with any one or more of:
shark cartilage, pharmacologically active shark extract, and chondroitin sulphate.
 4. A composition as claimed in either claim 1 or claim 2 which includes an anti-inflammatory agent in combination with a chondroitin compound.
- SUB C1*

- SUB
a)
5. A composition as claimed in either claim 1 or claim 2 which includes as the anti-inflammatory agent either or both of shark cartilage and pharmacologically active shark cartilage extract in combination with any one or more of:
Enzogenol™, Pycnogenol™, a bark extract equivalent to Enzogenol™ or Pycnogenol™, chondroitin sulphate, and a chondroitin compound.
 6. A composition as claimed in any one of the preceding claims which includes, as an enhancing agent, Pycnogenol™.
 7. A composition as claimed in any one of the preceding claims which includes one or more anti-oxidants other than Enzogenol or equivalent bark extracts.
 8. A composition as claimed in claim 7 in which an anti-oxidant is vitamin E.
 9. A composition as claimed in any one of the preceding claims which includes deer velvet or a pharmacologically active extract thereof.
 10. A composition as claimed in any one of the preceding claims which includes additional glycosaminoglycans than those present in the selected anti-inflammatory or enhancing agents.
 11. A composition as claimed in any one of the preceding claims which green-lipped mussel extract (GLME) and/or a pharmacologically active green lipped mussel product in sufficient amount to provide gastro-intestinal protection against irritation by other components in the composition.
 12. A composition as claimed in any one of the preceding claims which also includes any one or more of the following components:
a vitamin, glycine, lysine, methionine, glutamic acid, tyrosine, and compounds providing in a pharmacologically acceptable form one or more of the following elements: manganese, zinc, iron, magnesium, selenium, calcium, copper, potassium, cobalt.
 13. A composition as claimed in any one of the preceding claims which includes one or more pharmacologically active substances.

14. A composition as claimed in claim 13 in which a pharmacologically active substance is an anti-inflammatory other than those listed in claim 1.
15. A composition as claimed in any one of the preceding claims formulated to be suitable for addressing any one or more of the following conditions in animals: inflammation, arthritis, chronic joint pain.
16. A composition as claimed in any one of the preceding claims in any one or more of the following forms:
as a bolus or tablet, in a capsule, as a slow release implant, as a liquid composition, as a gel, and as a paste.
17. A composition as claimed in any one of the preceding claims formulated for use with non-human mammals.
18. A method for addressing joint problems in non-human animals consisting of the administration of a composition as claimed in any one of the preceding claims.
19. A method as claimed in claim 18 in which the method of administration is oral.
20. A composition substantially as described herein with reference to the contained examples.
21. A method for addressing joint problems, substantially as described herein with reference to the contained examples.
22. The use of any two or more of:
- i) green-lipped mussel extract (GLME) and/or a pharmacologically active green lipped mussel product,
 - ii) shark cartilage and/or pharmacologically active shark cartilage extract; and
 - iii) an antioxidant bark extract,
- in the preparation of a composition for use in addressing any one or more of:
- a) inflammation;
 - b) degenerative joint complaints;
 - c) other cartiligenous degeneration;
 - d) gastrointestinal sensitivity or irritation;
 - e) cancerous tumours;